Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain drug could cut opioid use after stomach surgery

NCT ID NCT07330063

Symptom relief Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new painkiller called anrikefon in 114 people recovering from laparoscopic stomach cancer surgery. The drug aims to control pain with fewer side effects like nausea and drowsiness than standard opioids. Researchers will measure how much extra opioid pain medicine patients need and how well they tolerate the treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anrikefon (Anruikefen)
What this could lead to
If successful, anrikefon could offer a safer way to manage pain after stomach surgery, with fewer side effects like nausea and less need for strong opioids.
What could go wrong
This is a small, early-stage trial (Phase 2) with only 114 participants. The drug is already approved in China for abdominal surgery pain, but results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 114 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18 and 70 years old (inclusive). * American Society of Anesthesiologists (ASA) physical status classification Class I-III. * Body Mass Index (BMI) ranging from 18 kg/m² to 30 kg/m² (inclusive). * Patients scheduled for elective total laparoscopic distal gastrectomy for gastric cancer under general anesthesia, with surgical duration \< 5 hours. * Surgical incision length \< 8 cm. * Voluntarily agree to participate in the trial and sign the informed consent form. Exclusion Criteria: * Patients undergoing emergency surgery or suffering from trauma. * Patients who undergo conversion to open surgery or laparoscopically assisted distal gastrectomy for gastric cancer during the operation. * Patients who refuse to receive Patient-Controlled Intravenous Analgesia (PCIA). * Patients with a history of prior abdominal surgery. * Patients expected to require prolonged endotracheal intubation after surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrectomy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrectomy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, 不限, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.